GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (HKSE:01093) » Definitions » 14-Day RSI

CSPC Pharmaceutical Group (HKSE:01093) 14-Day RSI : 40.84 (As of Dec. 12, 2024)


View and export this data going back to 1994. Start your Free Trial

What is CSPC Pharmaceutical Group 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-12), CSPC Pharmaceutical Group's 14-Day RSI is 40.84.

The industry rank for CSPC Pharmaceutical Group's 14-Day RSI or its related term are showing as below:

HKSE:01093's 14-Day RSI is ranked better than
98.81% of 1096 companies
in the Drug Manufacturers industry
Industry Median: 49.19 vs HKSE:01093: 40.84

Competitive Comparison of CSPC Pharmaceutical Group's 14-Day RSI

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSPC Pharmaceutical Group's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's 14-Day RSI falls into.



CSPC Pharmaceutical Group  (HKSE:01093) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSPC Pharmaceutical Group  (HKSE:01093) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


CSPC Pharmaceutical Group 14-Day RSI Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


CSPC Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Cai Dong Chen 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Blackrock, Inc. 2201 Interest of corporation controlled by you
True Ally Holdings Limited 2201 Interest of corporation controlled by you
Gong Cheng Guo Ji You Xian Gong Si 2101 Beneficial owner
Ding Da Ji Tuan You Xian Gong Si 2101 Beneficial owner

CSPC Pharmaceutical Group Headlines

No Headlines